Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Appoints Roche Alumnus; Gene-IT Hires Euro Sales Director; Codon Names Bioinformatics Director; and Others

NEW YORK (GenomeWeb News) — Invetech has named Alex Zrolka vice president of business development for the company’s North American life sciences division, the firm said this week.
 
Zrolka previously worked in marketing management, business development, and sales for Biotech Envoy, Genicon Sciences, Qiagen, Bio-Rad Laboratories, and DNAStar.  

 
Sequenom has appointed Steven Owings to vice president of commercial development for the company’s prenatal development division, the company said this week.
 
Owings will oversee commercialization of prenatal diagnostics such as Sequenom’s upcoming fetal Rhesus D typing test.
 
Owings comes to Sequenom after spending nearly 20 years at Roche, with five of those years spent as director of Roche’s PCR business unit. Owings also was a vice president of sales and marketing at Digene, and was in sales and marketing at Visible Genetics.

 
Gene-IT said this week it has named Oliver Bayliss to the position of director of European sales.
 
In the post, Bayliss will help push international sales for the company’s GenomeQuest sequencing software.
 
Bayliss previously served in worldwide sales at BioWisdom and was a sales leader at DNAStar, Oxford Molecular, Accelrys, and at Viaken.

 
OVP Venture Partners has tapped Carl Weissman to join the company. He will focus on investing in digital biology and “the convergence of IT, nanotechnology, and biotechnology,” the company said.
 
Weissman is currently CEO and president of Seattle-based Accelerator, a venture capital investment vehicle. OVP said Weissman will maintain his post at Accelerator while assuming his partner duties at OVP.

 
Codon Devices has named Stan Letovsky executive director of bioinformatics and information technology, the company said this week.
 
Letovsky most recently was senior director of computational sciences at Millennium Pharmaceuticals.
 
He also was in global bioinformatics with Monsanto and worked on the Genome Database Project at Johns Hopkins Medical Institute.   

 
Baird Venture Partners has hired Gregg Fergus to serve as an executive investment advisor for its healthcare and life sciences unit, parent company Robert W. Baird & Co. said this week.
 
Fergus also will take on the position of senior vice president of corporate development at Caden Biosciences, one of the company’s in Baird’s private-equity portfolio.

Kevin Sayer will join the board of directors at Eksigent, the company said this week.
 
Sayer, a biotech and pharmaceutical industry consultant, was named to the board as part of the company’s expansion of its medical devices segment, Eksigent said.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.